Core Insights - Abpro Holdings, Inc. has received an extension from the Nasdaq Hearings Panel to regain compliance with Nasdaq listing requirements, indicating progress in its turnaround strategy and pipeline advancement [1][2] Compliance and Financial Strategy - The company has implemented a reverse stock split and is pursuing a market transfer application as part of its compliance roadmap [2] - Abpro has access to up to $44 million in equity financing to support operations and achieve long-term financial goals [2][6] Operational Efficiency - Abpro has achieved an estimated 60% reduction in operating expenses compared to the previous year through disciplined streamlining [6] Pipeline Development - The lead antibody candidate, ABP-102, is on track for first-in-human trials in 2026, developed in partnership with Celltrion [6] - The company is advancing its proprietary DiversImmune and MultiMab™ platforms to enhance the selectivity and safety profiles of its antibody therapies [6] Management Perspective - The CEO of Abpro emphasized the importance of the extension for continuing the compliance plan and executing the company's strategy for sustainable growth [2][4]

Core Insights - Abpro Corporation and Celltrion, Inc. are set to present new preclinical data for CT-P72/ABP-102, a bispecific antibody targeting HER2 and CD3, at the SITC 2025 Annual Meeting [1][2] Group 1: Presentation Details - The preclinical results will be showcased at SITC 2025, following a prior presentation at the AACR New Drugs on the Horizon Session earlier this year [2] - The CT-P72/ABP-102 poster has been selected as one of the Top 150 abstracts from over 1,300 submissions at SITC 2025 [3] Group 2: Key Findings - CT-P72/ABP-102 demonstrates potent and selective anti-tumor activity in HER2-high models, including those resistant to Enhertu [7] - The dual-affinity engineering of CT-P72/ABP-102 reduces on-target, off-tumor activity, supporting a favorable preclinical safety profile [7] - Strong preclinical activity has been observed in vivo, including efficacy in Enhertu-resistant models [9] Group 3: Safety and Efficacy - A GLP repeated-dose toxicity study in cynomolgus monkeys showed good tolerability at all tested doses, including the highest dose of 80 mg/kg, indicating a favorable safety profile [10] - The molecule has shown robust T-cell activation and PBMC-mediated cytotoxicity in vitro, confirming enhanced tumor selectivity [9] Group 4: Development and Collaboration - Abpro and Celltrion are collaborating to develop CT-P72/ABP-102, which is built on Abpro's DiversImmune platform, aimed at improving selectivity and safety in antibody therapies [11][12] - The companies are working towards assembling a robust IND submission package to initiate the first-in-human trial for CT-P72/ABP-102 next year [5]